Oxidative stress, Anti-melanocyte and anti tyrosinase antibody in vitiligo and response to treatment

Abstract

Vitiligo is an acquired, usually asymptomatic pigmentary disorder that results in the loss of functional melanocytes and is often associated with other autoimmune diseases. At the onset of the disease white patches of different sizes appear on different parts of the body. Vitiligo usually affects the skin, but it can develop anywhere we have pigment. Patches of hair can turn white. Some people lose color inside their mouths. The affected skin can lighten or turn completely white. Vitiligo affects approximately 1% of the world population of all skin types, usually before the age of 20. In this case-control study (100) patients with vitiligo which divided in to two subgroups (treated with topical, systemic steroid and treated with narrow band phototherapy), and (50) healthy control were examined. VASI score for each patient was calculated. Serum levels of GPx activity & TAC were measured by spectrophotometer,but MC-Ab & TYR-Ab aweremeasured by ELIZA. After measurements and comparison between vitiligo patients and ageandgender matched control group, results showed significant differences in glutathione peroxidase activity, total antioxidant capacity, anti-melanocyte antibody and anti tyrosinase antibody among these groups. There was significant increase in serum GPx activity, TAC, MC-Ab and TYR-Ab (P value = < 0.001, 0.003, < 0.001 and < 0.001 for glutathione peroxidase activity, total antioxidant capacity, anti-melanocyte antibody and anti tyrosinase antibody respectively) for vitiligo patients as compared with control group. After measurements and comparison between vitiligo patients subgroups results showed significant increase in serum GPxactivity among NB-UVB group, but no significant differences in TAC, MC-Ab and TYR-Ab were showed when comparison between vitiligo patients subgroups. There was significant increase in serum GPx activity (P value = <0.001) for vitiligo patients treated with NB-UVB group as compared with vitiligo patients treated with steroid group.